- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Spectral CT System Gets FDA Clearance for Radiation Oncology Use
The Spectral CT 7500 RT system reportedly combines 4D conventional computed tomography (CT) with the enhanced quantification and visualization of spectral CT to facilitate improved precision with radiotherapy.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Spectral CT 7500 RT system, which enables clinicians to access the capabilities of 4D conventional computed tomography (CT) and spectral CT in one scan.
Geared to radiation oncology, the Spectral CT 7500 RT system bolsters tissue characterization with spectral CT, facilitating targeted radiotherapy, according to Philips, the manufacturer of the Spectral CT 7500 RT system.
The newly FDA-cleared Spectral CT 7500 RT system bolsters tissue characterization with spectral CT, and offers automated stopping-power ratio (SPR) mapping and direct electron density to improve the accuracy of radiotherapy dosing. (Image courtesy of Philips.)
Emphasizing that the Spectral CT 7500 RT system is the first radiation therapy CT platform to provide respiratory-gated spectral imaging, Philips said the system offers automated stopping-power ratio (SPR) mapping and direct electron density to improve the accuracy of radiotherapy dosing.
"The Spectral CT system provides us with several capabilities that conventional CT does not have. It can provide electron density and effective atomic number results, which we can convert to the proton stopping-power ratio. And published data shows that the stopping power ratio obtained in this way has fewer uncertainties compared to regular calibration curves, thereby reducing the uncertainty margins during treatment planning," noted Zhong Su, Ph.D., the physics director in the Department of Radiation Oncology at the University of Arkansas for Medical Sciences (UAMS) Medical Center in Little Rock, Arkansas.
Philips noted the Spectral CT 7500 RT system will be showcased at the upcoming Radiological Society of North America (RSNA) Annual Meeting in Chicago December 1-5, 2024.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
